MBX Biosciences' Administrative Costs Reach $34.3 Million From $4.7 Million As Stock-Award Expense Climbs
Former-CEO award changes added $20.8 million in expense, while MBX expects its cash and investments to fund operations into 2029.
MBX Biosciences, which develops peptide drugs for hormone disorders and obesity, spent $34.3 million on administration in the third quarter, compared with $4.7 million a year earlier, with changes to its former CEO's stock awards accounting for $20.8 million. Its unaudited quarterly loss widened to $62.4 million from $21.6 million, according to Monday's SEC earnings filing.
Stock Awards And Trial Bills
MBX's loss amounted to $1.29 per share, compared with $0.63 a year earlier. Administrative expenses increased by $29.6 million; alongside the award-related compensation expense, MBX attributed higher personnel costs to expansion of its executive team and the infrastructure supporting its operations.
Research and development spending reached $32.0 million, up $12.7 million from $19.3 million. MBX attributed that increase to starting the late-stage canvuparatide trial, continuing its extension study and the early-stage MBX 4291 obesity trial, and preclinical work on MBX 5765 and MBX 6180.
For the first nine months, MBX lost $123.0 million, compared with $64.9 million in the same period of 2025. Research spending over that period was $81.5 million versus $59.4 million, while administrative spending reached $53.0 million from $12.9 million.
Stock Sales Fund The Pipeline
MBX had cash and investments of $481.6 million at September 30, compared with $373.7 million at December 31, 2025. That balance included $97.6 million in net proceeds from common shares sold through its market-sale agreement. Management expects the money to cover operations into 2029 under its current spending plan.
MBX has no approved products. Its Precision Endocrine Peptide platform is designed to make drugs last longer in the body and reduce how often patients need doses; the company retains global commercial rights to all its programs.
Canvuparatide is being developed as a weekly injection for chronic hypoparathyroidism, a rare disorder involving too little parathyroid hormone. MBX started patient dosing in its late-stage trial in August, following positive mid-stage results and benefits sustained through a year of extension-study treatment.
The global study is expected to enroll approximately 160 adults and compare canvuparatide with a placebo. Its main assessment at 26 weeks includes normal blood calcium, independence from active vitamin D, limited calcium supplementation and no dose increases or rescue treatment during the final four weeks.
Monthly Obesity Dosing Faces A Test
MBX expects results in the fourth quarter of 2026 from the first cohort in the 12-week portion of its early-stage MBX 4291 trial. Participants receive 30 milligrams weekly for four weeks, then monthly doses of 120 and 180 milligrams.
Steve Hoerter, MBX's chairman and chief executive officer, said the drug is designed for monthly dosing and has “the potential to offer improved gastrointestinal tolerability.” That remains a development goal, rather than an established treatment benefit.
The company's presentation describes preliminary, still-blinded results from an earlier cohort: mean weight loss was 7% at eight weeks among eight participants, including two receiving placebo. One participant experienced mild diarrhea; no nausea, vomiting or serious adverse events were reported.
MBX is also conducting studies needed to support human testing of MBX 5765 and MBX 6180, both designed for monthly obesity dosing.
MBX expects to present preclinical MBX 6180 drug-exposure data at ObesityWeek in Washington, D.C., November 14–17. The next scheduled human-data readout is the fourth-quarter MBX 4291 result.
Sources
- 8-K Filing — MBX Biosciences, Inc. (MBX) — SEC EDGAR
- Exhibit mbx-ex99_1.htm — MBX Biosciences, Inc. 8-K exhibit — SEC EDGAR
- Exhibit mbx-ex99_2.htm — MBX Biosciences, Inc. 8-K exhibit — SEC EDGAR
- MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights — Yahoo Finance
- MBX Biosciences Reports Third Quarter 2026 Financial — globenewswire.com
- 8-K filed 2026-08-27 — MBX Biosciences, Inc. (earlier disclosure) — SEC EDGAR